{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T16:21:30Z","timestamp":1773159690216,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T00:00:00Z","timestamp":1576540800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T00:00:00Z","timestamp":1576540800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s12185-019-02793-w","type":"journal-article","created":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T18:02:51Z","timestamp":1576605771000},"page":"585-590","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Safe administration of rituximab for follicular lymphoma after obinutuzumab infusion-related reaction"],"prefix":"10.1007","volume":"111","author":[{"given":"Takeshi","family":"Hara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryohei","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihisa","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kengo","family":"Yamakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasumasa","family":"Yamagishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Sobajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rie","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rie","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Murayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9262-5790","authenticated-orcid":false,"given":"Hisashi","family":"Tsurumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,17]]},"reference":[{"key":"2793_CR1","first-page":"266","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"ES Jaffe","year":"2017","unstructured":"Jaffe ES, Harris NL, Swerdlow SH, Olt G, Nathwani BN, de Jong D, et al. Follicular lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2017. p. 266\u2013277."},{"key":"2793_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.7326\/0003-4819-90-1-10","volume":"90","author":"CS Portlock","year":"1979","unstructured":"Portlock CS, Rosenberg SA. No initial therapy for stage III and IV non-Hodgkin\u2019s lymphomas of favorable histologic types. Ann Intern Med. 1979;90:10\u20133.","journal-title":"Ann Intern Med"},{"key":"2793_CR3","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1056\/NEJM198412063112303","volume":"311","author":"SJ Horning","year":"1984","unstructured":"Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin\u2019s lymphomas. N Engl J Med. 1984;311:1471\u20135.","journal-title":"N Engl J Med"},{"key":"2793_CR4","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","volume":"15","author":"P Brice","year":"1997","unstructured":"Brice P, Bastion Y, Lepage E, Brousse N, Ha\u00efoun C, Moreau P, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. J Clin Oncol. 1997;15:1110\u20137.","journal-title":"J Clin Oncol"},{"key":"2793_CR5","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1200\/JCO.1998.16.7.2332","volume":"16","author":"P Solal-C\u00e9ligny","year":"1998","unstructured":"Solal-C\u00e9ligny P, Lepage E, Brousse N, Tendler CL, Brice P, Ha\u00efoun C, et al. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d\u2019Etude des Lymphomes Folliculaires 86 Trial. J Clin Oncol. 1998;16:2332\u20138.","journal-title":"J Clin Oncol"},{"key":"2793_CR6","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1182\/blood-2006-03-013193","volume":"108","author":"C Sebban","year":"2006","unstructured":"Sebban C, Mounier N, Brousse N, Belanger C, Brice P, Haioun C, et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma : the GELF-94 randomized study from the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA). Blood. 2006;108:2540\u20134.","journal-title":"Blood"},{"key":"2793_CR7","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2011","unstructured":"Salles G, Seymour JF, Offner F, L\u00f3pez-Guillermo A, Belada D, Xerri L, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377:42\u201351.","journal-title":"Lancet"},{"key":"2793_CR8","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"W Hiddemann","year":"2005","unstructured":"Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725\u201332.","journal-title":"Blood"},{"key":"2793_CR9","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","volume":"26","author":"R Marcus","year":"2008","unstructured":"Marcus R, Imrie K, Solal-Celigny P, Catalano JV, Dmoszynska A, Raposo JC, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008;26:4579\u201386.","journal-title":"J Clin Oncol"},{"key":"2793_CR10","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, et al. Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123:2944\u201352.","journal-title":"Blood"},{"key":"2793_CR11","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Gr\u00fcnhagen U, Losem C, Study group indolent Lymphomas (StiL), et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203\u201310.","journal-title":"Lancet"},{"key":"2793_CR12","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1158\/1535-7163.MCT-12-1182","volume":"12","author":"S Herter","year":"2013","unstructured":"Herter S, Herting F, Mundigl O, Waldhauer I, Weinzierl T, Fauti T, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and of atumumab in vitro and in xenograft models. Mol Cancer Ther. 2013;12:2031\u201342.","journal-title":"Mol Cancer Ther"},{"key":"2793_CR13","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","volume":"115","author":"E M\u00f6ssner","year":"2010","unstructured":"M\u00f6ssner E, Br\u00fcnker P, Moser S, P\u00fcntenerv U, Schmidt C, Herter S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010;115:4393\u2013402.","journal-title":"Blood"},{"key":"2793_CR14","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-C\u00e9ligny","year":"2004","unstructured":"Solal-C\u00e9ligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258\u201365.","journal-title":"Blood"},{"key":"2793_CR15","unstructured":"Institute. NC. Common Terminology Criteria for Adverse Events version 4.0. http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed 14 Sept 2015."},{"key":"2793_CR16","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/S1386-6346(03)00232-8","volume":"37","author":"H Takikawa","year":"2003","unstructured":"Takikawa H, Takamori Y, Kumagi T, Onji M, Watanabe M, Shibuya A, et al. Assessment of 287 Japanese cases of drug induced liver injury by the diagnostic scale of the international consensus meeting. Hepatol Res. 2003;37:192\u20135.","journal-title":"Hepatol Res"},{"key":"2793_CR17","doi-asserted-by":"publisher","first-page":"3482","DOI":"10.1182\/blood-2013-05-504043","volume":"122","author":"J Golay","year":"2013","unstructured":"Golay J, Da Roit F, Bologna L, Ferrara C, Leusen JH, Rambaldi A, et al. Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood. 2013;122:3482\u201391.","journal-title":"Blood"},{"key":"2793_CR18","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","volume":"115","author":"E M\u00f6ssner","year":"2010","unstructured":"M\u00f6ssner E, Br\u00fcnker P, Moser S, P\u00fcntener U, Schmidt C, Herter S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010;115:4393\u2013402.","journal-title":"Blood"},{"key":"2793_CR19","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1365-2141.2010.08428.x","volume":"152","author":"M Patz","year":"2011","unstructured":"Patz M, Isaeva P, Forcob N, M\u00fcller B, Frenzel LP, Wendtner CM, et al. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells. Br J Haematol. 2011;152:295\u2013306.","journal-title":"Br J Haematol"},{"key":"2793_CR20","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1634\/theoncologist.12-5-601","volume":"12","author":"H-J Lenz","year":"2007","unstructured":"Lenz H-J. Management and preparedness for infusion and hypersensitivity reactions. Oncologist. 2007;12:601\u20139.","journal-title":"Oncologist"},{"key":"2793_CR21","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1023\/A:1006341717398","volume":"18","author":"RO Dillman","year":"1999","unstructured":"Dillman RO. Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev. 1999;18:465\u201371.","journal-title":"Cancer Metastasis Rev"},{"key":"2793_CR22","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","volume":"377","author":"R Marcus","year":"2017","unstructured":"Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017;377:1331\u2013444.","journal-title":"N Engl J Med"},{"key":"2793_CR23","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s12185-018-2497-0","volume":"108","author":"K Ohmachi","year":"2018","unstructured":"Ohmachi K, Tobinai K, Kinoshita T, Ishikawa T, Hatake K, Ichikawa S, et al. Efficacy and safety of obinutuzumab in patients with previously untreated follicular lymphoma: a subgroup analysis of patients enrolled in Japan in the randomized phase III GALLIUM trial. Int J Hematol. 2018;108:499\u2013509.","journal-title":"Int J Hematol"},{"key":"2793_CR24","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1188\/10.CJON.E10-E21","volume":"14","author":"WH Vogel","year":"2010","unstructured":"Vogel WH. Infusion reactions: diagnosis, assessment, and management. Clin J Oncol Nurs. 2010;14:10\u2013211.","journal-title":"Clin J Oncol Nurs"},{"key":"2793_CR25","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1188\/16.CJON.E41-E48","volume":"20","author":"K Dawson","year":"2016","unstructured":"Dawson K, Moran M, Guindon K, Wan H. Managing infusion-related reactions for patients with chronic lymphocytic leukemia receiving obinutuzumab. Clin J Oncol Nurs. 2016;20:41\u20138.","journal-title":"Clin J Oncol Nurs"},{"key":"2793_CR26","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","volume":"17","author":"LH Sehn","year":"2016","unstructured":"Sehn LH, Chua N, Mayer J, Dueck G, Trn\u011bn\u00fd M, Bouabdallah K, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol. 2016;17:1081\u201393.","journal-title":"Lancet Oncol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-019-02793-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-019-02793-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-019-02793-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T01:20:13Z","timestamp":1608081613000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-019-02793-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,17]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["2793"],"URL":"https:\/\/doi.org\/10.1007\/s12185-019-02793-w","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,17]]},"assertion":[{"value":"8 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}